Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer.

ABSTRACT:

Background

Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer remains a significant clinical problem. Riluzole is FDA-approved for the treatment of amyotrophic lateral sclerosis. A benzothiazole-based glutamate release inhibitor with several context-dependent mechanism(s) of action, riluzole has shown antitumor activity in multiple malignancies, including melanoma, glioblastoma, and breast cancer. We previously reported that the acquisition of tamoxifen resistance in a cellular model of invasive lobular breast cancer is accompanied by the upregulation of GRM mRNA expression and growth inhibition by riluzole.

Methods

We tested the ability of riluzole to reduce cell growth, alone and in combination with endocrine therapy, in a diverse set of ER+

SUBMITTER: Olukoya AO 

PROVIDER: S-EPMC10521904 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature